A Phase 4 interventional study of Extended infusion time of the following beta-lactam: meropenem and Short-term infusion time of the following beta-lactam: meropenem in Infection, Sepsis and NICU, sponsored by Semmelweis University. Recruiting at 2 sites in Hungary. Open to participants aged 0 Hours to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Semmelweis University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Sepsis with a site in Hungary — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Hungary.
Among the 22 studies in Sepsis with a site in Hungary, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 21st registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →4 of the 22 studies in Sepsis with a site in Hungary are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Hungary, United States, Argentina and 11 more countries
Ages 18–80
Semmelweis University · Sites in Hungary
Ages 18+
Semmelweis University · Sites in Hungary
Ages 18–80
A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 0 Hours to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 2 · Phase 4 3
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 130 across the 16 interventional studies, 213 across the 6 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 22 have an industry lead sponsor. The 10 most frequent:
Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.
Semmelweis University has 3 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Hungary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Sepsis with a site in Hungary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.
The main question it aims to answer is:
Is the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.
Participants will:
Treatment begins with a short, intermittent infusion of antibiotics. If the patient meets study criteria, randomisation must occur within 24 hours. Prior to enrolment, written informed consent or a declaration of contribution must be signed by the legal guardian and, where age-appropriate, the patient.
Plans for the collection and laboratory evaluation of biological samples:
Per protocol:
This study involves collecting blood samples (200 µl per sample) to monitor drug levels, with each sample identified by the patient's assigned PIN (Personal Identification Number). To ensure measurements reflect steady-state conditions, samples must be collected at least 48 hours after the first post-allocation dose and immediately prior to the next scheduled dose (trough or minimum level). Analysis of free (unbound) drug concentrations is performed via High-Performance Liquid Chromatography (HPLC) with specific absorbance detection for meropenem (290 nm), piperacillin (252 nm), tazobactam (210 nm), and cefepime (263 nm); ceftriaxone is measured using Liquid Chromatography-Mass Spectrometry (LC-MS).
For evaluating the drug levels:
Pathogen minimal inhibitory concentration (MIC) values will be sourced directly from the microbiology laboratory when available; otherwise, values will be retrieved from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) database. In place of a measured MIC, the epidemiological cut-off value (ECOFF)-representing the upper MIC limit for wild-type, non-resistant bacteria-may be used. For empirical dosing where no specific pathogen is identified, the highest MIC for antibiotic-susceptible bacteria will be applied to account for a worst-case scenario.
Standard care:
Routine laboratory assessments-including a complete blood count (CBC) and blood chemistry tests-will be conducted at enrolment and daily thereafter. To ensure accuracy, samples must be analysed within 1-2 hours of collection. Baseline data will include inflammatory markers (C-reactive protein [CRP], procalcitonin [PCT]), hematological parameters (white blood cell count [WBC], platelet count), liver function (liver enzymes and total/direct bilirubin), and serum creatinine. Additionally, clinical severity will be assessed using Paediatric Index of Mortality 3 (PIM-3), Paediatric Risk of Mortality III (PRISM III), and Paediatric Logistic Organ Dysfunction 2 (PELOD 2) scores. While all patients require a pre-antibiotic blood culture, those with negative cultures will be excluded from the microbiological eradication analysis.
In cases where microbiological cultures are negative, the clinician will diagnose infection based on clinical signs and symptoms. These signs and symptoms will also be examined when assessing the clinical response outcome.
Signs of infection may include elevated acute phase proteins (CRP > 10 mg/L or PCT > 0.5 µg/L or WBC > 10,000 /µL), or infection/inflammation confirmed by imaging and any clinical signs (fever > 37.5 °C core temperature or haemodynamic instability - need for inotropic or vasopressor therapy or abnormal blood gas values (normal arterial blood gas values: pH=7.35-7.45, PaO2=80-100 mmHg, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L and lactate\<3 mmol/L; normal venous blood gas values: pH=7.31-7.41, PvO2=35-45 mmHg, PCO2=41-51 mmHg, [HCO3-]=22-28 mEq/L and lactate\<3 mmol/L; normal capillary blood gas values: pH=7.35-7.45, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L) or respiratory failure or neurological signs or enteral feeding intolerance.
Criteria for discontinuation or modification of designated interventions:
If blood samples reveal sub-therapeutic antibiotic levels (underexposure), dosing must be adjusted by increasing the dose or the frequency of administration. All adjustments must be documented. Patients requiring these changes will remain in their originally assigned study arm for analysis under the modified intention-to-treat (mITT) population; crossover between study arms is strictly prohibited. In the event of clinician-reported adverse events, the Steering Committee (SC) will determine whether the antibiotic should be discontinued.
If β-lactam therapy must be changed due to clinical deterioration or antibiotic resistance, and the new antibiotic is also a study β-lactam (meropenem, piperacillin/tazobactam, cefepime, or ceftriaxone), the patient remains in the assigned arm (extended infusion [EI] or short-term infusion [SI]) and is not excluded.
All patients are followed for 30 days post-allocation or until discharge or death. For patients discharged before the 30-day mark, a telephone follow-up will be conducted on day 30 to evaluate their clinical status.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's planned enrollment of 110 is close to the median of 102 across 1,169 interventional studies indexed under Sepsis.
Browse Sepsis studies →Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age
Drug: Short-term infusion time of the following beta-lactam: meropenem · Drug: Short-term infusion time of the following beta-lactam: piperacillin/tazobactam · Drug: Short-term infusion time of the following beta-lactam: cefepime · Drug: Short-term infusion time of the following beta-lactam: ceftriaxone
subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age
Drug: Extended infusion time of the following beta-lactam: meropenem · Drug: Extended infusion time of the following beta-lactam: piperacillin/tazobactam · Drug: Extended infusion time of the following beta-lactam: cefepime · Drug: Extended infusion time of the following beta-lactam: ceftriaxone
Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- cefepime (CFP): 30-50 mg/kg q8h or q12h (\>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose \[q8h\] used for severe infection and febrile neutropenia) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group extended infusion (EI): Duration of infusion is 3 hours (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- cefepime (CFP): 30-50 mg/kg q8h or q12h (\>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose \[q8h\] used for severe infection and febrile neutropenia) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Group short-term infusion (SI): Duration of infusion is 0.5 hour (h) Subset paediatric (P): The doses of beta-lactams are (q…h= every…hours): \- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day) Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.
Proportion of patients achieving PK/PD index: 100% fT>MIC (Ctrough >MIC)
In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the minimal inhibitory concentration (MIC) of the bacterium isolated throughout the dosing interval (100% fT\>1-4×MIC). The primary outcome for the study will be the proportion of patients achieving therapeutic and optimal drug exposure, defined as plasma concentrations above the MIC for 100% of the dosing interval. Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT\>MIC (Ctrough \>MIC).
Time frame: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation
Proportion of patients achieving PK/PD index: 100% fT>4xMIC (Ctrough >4xMIC)
In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the MIC (minimal inhibitory concentration) of the bacterium isolated throughout the dosing interval (100% fT\>1-4×MIC). Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT\>4xMIC (Ctrough \>4xMIC).
Time frame: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation
Time to normalisation of C-reactive protein (CRP)
It shows how many days it takes for CRP to return to normal (\<10 mg/L).
Time frame: From enrollment to the end of treatment (maximum 30 days).
Time to normalisation of procalcitonin (PCT)
It shows how many days it takes for PCT to return to normal (\<0.5 µg/L).
Time frame: From enrollment to the end of treatment (maximum 30 days).
Time to normalisation of white blood cells (WBC)
It shows how many days it takes for WBC to return to normal (\<10,000 /µl).
Time frame: From enrollment to the end of treatment (maximum 30 days).
Microbiological eradication rate
Blood culture must be taken from each patient before starting antibiotic treatment. Additional samples should be taken according to the regimen mentioned below.
Time frame: On day 0 before initiation of antibiotic treatment and on days 2, 3 and 5 after initiation of antibiotic treatment
Clinical response
Resolution (or clinical success): disappearance of all signs and symptoms related to the infection. * Improvement: a marked or moderate reduction in the severity and/or number of signs and symptoms of infection. * Failure: reduction in signs and symptoms of infection is not sufficient to meet the criteria for improvement, which encompasses outcomes such as death or cases where evaluation was not feasible for any reason.
Time frame: Each day from enrollment to the end of treatment (maximum 30 days).
Time to clinical success or resolution
It shows how many days it takes to achieve clinical success or resolution.
Time frame: From enrollment to the end of treatment (maximum 30 days).
Treatment failure
Number of patients for whom the β-lactam antibiotic therapy had to be discontinued due to clinical deterioration and/or antibiotic resistance. If the newly initiated β-lactam is also among the study β-lactams (meropenem, piperacillin/ tazobactam, cefepime, and ceftriaxone), the patient remains in the originally assigned treatment arm (EI or SI).
Time frame: From enrollment to the end of treatment (maximum 30 days).
Duration of the antibiotic therapy
It shows how many days the antibiotic had to be administered.
Time frame: From enrollment to the end of treatment (maximum 30 days).
Length of PICU/NICU stay in hours
It shows how many hours passed from admission to discharge. PICU=Pediatric Intensive Care Unit NICU=Neonatal Intensive Care Unit
Time frame: From enrollment to the end of treatment (maximum 30 days).
Length of hospital stay (LOS) in days
It shows how many days passed from admission to discharge.
Time frame: From enrollment to the end of treatment (maximum 30 days).
All-cause mortality
The total number of deaths from any cause.
Time frame: From enrollment to the end of treatment (maximum 30 days).
Adverse events (AEs)
Definition of adverse event: any harmful, undesirable, potentially severe, or life-threatening effects occurring during or after the administration of the antibiotics proposed in this study. They will be collected in a form where all AEs are listed according to the Summary of Product Characteristics (SmPCs).
Time frame: Each day from enrollment to the end of treatment (maximum 30 days).
Plan to share: Yes — After publication, the IPD that underlie the results will be available upon request in encrypted form, subject to approval by the corresponding author.
Time frame: Data will be available immediately following publication with no end date.
Access criteria: Data will be made available to investigators who submit a request for data access for specific aims, subject to approval by the corresponding author. A proposal that describes planned analyses must be submitted to the the corresponding author.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.
Of 65 non-industry phase 4 interventional studies under Sepsis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 23 months is close to that.
Counting every sponsor, half of 66 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Apr 2026 → Sep 2026, primary completion Apr 2028 → Aug 2028 and completion Apr 2028 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.